Stay updated on ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Locations now list California, District of Columbia, Florida, Michigan, and Tennessee. The HHS Vulnerability Disclosure link was removed and the page revision updated to v3.3.3.
    Difference
    0.7%
    Check dated 2025-12-23T20:41:47.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    30 days ago
    Change Detected
    Summary
    Revision updated from v3.2.0 to v3.3.2 on the study page; no substantive content changes to the study details or eligibility criteria are evident. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-25T13:59:42.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    The banner about government funding and data currency was removed from the page. No study details, eligibility criteria, locations, or outcomes were altered. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-18T07:24:42.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    The page appears to have no significant changes to core study information (eligibility, endpoints, locations, or status); only minor layout/UI adjustments are visible. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2025-10-27T21:03:51.000Z thumbnail image
  7. Check
    81 days ago
    Change Detected
    Summary
    Core content updated to include a government-funding operating status advisory and a new revision/version (v3.2.0); previous update label and old revision (v3.1.0) were removed.
    Difference
    4%
    Check dated 2025-10-06T08:12:57.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    The page has been updated with newer revision details (v3.1.0), dates, and policy notes (IPD plan), while older statuses and legacy dates (e.g., Active, not recruiting; 2024 dates) were removed. This signals an update to product information and governance without altering core content.
    Difference
    3%
    Check dated 2025-09-29T04:38:54.000Z thumbnail image

Stay in the know with updates to ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page.